...
机译:地区对接受PD-1 / PD-L1抑制剂患者的疗效的影响
Nanjing Univ Chinese Med Dept Spine Wuxi Hosp Wuxi 214000 Jiangsu Peoples R China;
Nantong Univ Med Sch Nantong 226001 Peoples R China;
Nanjing Univ Chinese Med Dept Spine Wuxi Hosp Wuxi 214000 Jiangsu Peoples R China;
Nantong Univ Dept Med Xinling Coll Nantong 226001 Jiangsu Peoples R China;
Nantong Univ Dept Med Xinling Coll Nantong 226001 Jiangsu Peoples R China;
Nantong Univ Med Sch Nantong 226001 Peoples R China;
Nanjing Univ Chinese Med Dept Spine Wuxi Hosp Wuxi 214000 Jiangsu Peoples R China;
Nanjing Univ Chinese Med Dept Spine Wuxi Hosp Wuxi 214000 Jiangsu Peoples R China;
Nanjing Univ Chinese Med Dept Spine Wuxi Hosp Wuxi 214000 Jiangsu Peoples R China;
Nantong Univ Med Sch Nantong 226001 Peoples R China;
Nanjing Univ Chinese Med Dept Spine Wuxi Hosp Wuxi 214000 Jiangsu Peoples R China;
Regional difference; PD-1/L1 inhibitors; North America; Europe; Overall survival;
机译:地区对接受PD-1 / PD-L1抑制剂患者的疗效的影响
机译:编程的细胞死亡蛋白1(PD-1)的结果和编程的死亡 - 配体1(PD-L1)抑制剂治疗HIV患者的晚期癌症
机译:患者报告的癌症PD-1 / PD-L1抑制剂的结果:META分析
机译:在局部晚期喉部或白阴癌患者的同时趋化后的功能结果
机译:吉西他滨联合顺铂一线化疗对晚期胆道癌患者治疗效果的预测因素
机译:HIV晚期癌症患者程序性细胞死亡蛋白1(PD-1)和程序性死亡配体1(PD-L1)抑制剂治疗的结果
机译:编程的细胞死亡蛋白1(PD-1)和编程死亡 - 配体1(PD-L1)抑制剂治疗患者的先进癌症的结果